falsefalse

Clinical Updates in Treating Advanced Prostate Cancer - Episode 7

Use of Bone Protection Agents

,

Panelists discuss how the PEACE-3 trial explores the efficacy of combining radium-223 with enzalutamide in advanced prostate cancer, highlighting its potential to enhance therapeutic outcomes and survival rates.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Treatment Landscape and Sequencing of Therapies
    EP. 2: Treatment Timelines Related to Disease State and Use of Monotherapy
    EP. 3: Genetic Testing – Germline
    EP. 4: Recent Data on ARPI-Based Combination Regimens
    EP. 5: Genetic Testing – Somatic
    EP. 6: ARPI-Based Combination Regimens – PEACE-3 (Radium-223 and enzalutamide)
    Now Viewing
    EP. 7: Use of Bone Protection Agents
    EP. 8: ARPI-Based Combination Regimens – ARANOTE (Darolutamide and ADT)
    EP. 9: ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)
    EP. 10: ARPI-Based Combination Regimens – SPLASH (177 Lu-PNT-2002)
    EP. 11: Key Takeaways and Looking Ahead

    Do you mandate for an mcrpc that all your patients on a bone health agent and antiresorptive, regardless of the therapy, and regardless of whether they have bone lesions?

    Related Content:

    Clinical Updates in Treating Advanced Prostate Cancer
    ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)
    ARPI-Based Combination Regimens – SPLASH (177 Lu-PNT-2002)
    Key Takeaways and Looking Ahead
    x